Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells
Abstract
:1. Introduction
2. Induced Pluripotent Stem Cell (iPSC)
2.1. Disease Modeling
2.2. Drug Screening
2.3. Regenerative Therapies
3. Limitations and Solutions for Translation of iPSC-CMs Practically
3.1. Overcoming iPSC-CMs Immaturity
3.2. Delivery Routes
3.3. Prevention of Immunogenicity
3.4. Solutions for Arrhythmogenesis
3.5. Solutions to Poor Engraftment
3.6. Prevention of Tumorigenesis
4. Current Therapeutic Clinical Trials
4.1. iPSC-Derived Cardiomyocyte Patch
4.2. Cardiac Spheroid
4.3. Biological Ventricular Assist Tissue (BioVAT)
4.4. Epicardial Injection of iPSC-CMs
5. Summary
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Shah, A.M.; Mann, D.L. In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science. Lancet 2011, 378, 704–712. [Google Scholar] [CrossRef] [PubMed]
- Heidenreich, P.A.; Fonarow, G.C.; Opsha, Y.; Sandhu, A.T.; Sweitzer, N.K.; Warraich, H.J.; HFSA Scientific Statement Committee Members Chair. Economic issues in heat failure in the United States. J. Card. Fail. 2022, 28, 453–466. [Google Scholar] [CrossRef] [PubMed]
- Roth, G.A.; Dorsey, H.; Decleene, N.; Razo, C.; Stark, B.; Johnson, C. The global burden of heart failure: A systematic analysis for The Global Burden of Disease Study 2021. Eur. Heart J. 2023, 44 (Suppl. 2), ehad655.876. [Google Scholar] [CrossRef]
- Bristow, M.R. Management of heart failure. In Braunwald’s Heart Disease; Elsevier: Amsterdam, The Netherlands, 2005; pp. 603–624. [Google Scholar]
- Starling, R.C. Epidemiology of heart failure: Progression to pandemic? Heart Fail. Comb. Med. Surg. Approach 2007, 1–8. [Google Scholar] [CrossRef]
- Urbich, M.; Globe, G.; Pantiri, K.; Heisen, M.; Bennison, C.; Wirtz, H.S.; Di Tanna, G.L. A systematic review of medical costs associated with heart failure in USA (2014–2020). Pharmacoeconomics 2020, 38, 1219–1236. [Google Scholar] [CrossRef] [PubMed]
- Murry, C.E.; Reinecke, H.; Pabon, L.M. Regeneration gaps: Observations on stem cells and cardiac repair. J. Am. Coll. Cardiol. 2006, 47, 1777–1785. [Google Scholar] [CrossRef]
- Laflamme, M.A.; Murry, C.E. Regenerating the heart. Nat. Biotechnol. 2005, 23, 845. [Google Scholar] [CrossRef]
- Hunt, S.A.; American College of Cardiology. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005, 112, e154–e235. [Google Scholar] [PubMed]
- Azevedo, P.S.; Polegato, B.F.; Minicucci, M.F.; Paiva, S.A.; Zornoff, L.A. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arq. Bras. Cardiol. 2016, 106, 62–69. [Google Scholar] [CrossRef]
- Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Blaha, M.J.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S. Heart disease and stroke statistics—Update: A report from the American Heart Association. Circulation 2014, 129, e28–e292. [Google Scholar]
- Joseph, A.; Kaplan, S. After Criticism from Scientists, Congress Eases Its Pursuit of Faster Stem Cell Therapies. Stat News. 2016. Available online: https://www.statnews.com/2016/11/30/stem-cells-cures-act/ (accessed on 25 May 2024).
- Romito, A.; Cobellis, G. Pluripotent stem cells: Current understanding and future directions. Stem Cells Int. 2016, 2016, 9451492. [Google Scholar] [CrossRef] [PubMed]
- Rikhtegar, R.; Pezeshkian, M.; Dolati, S.; Safaie, N.; Afrasiabi Rad, A.; Mahdipour, M.; Nouri, M.; Jodati, A.R.; Yousefi, M. Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs, and skeletal myoblasts. Biomed. Pharmacother. 2019, 109, 304–313. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663–676. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [Google Scholar] [CrossRef]
- Yuasa, S.; Fukuda, K. Cardiac regenerative medicine. Circ. J. 2008, 72, A49–A55. [Google Scholar] [CrossRef] [PubMed]
- Sayed, N.; Liu, C.; Wu, J.C. Translation of human-induced pluripotent stem cells: From clinical trial in a dish to precision medicine. J. Am. Coll. Cardiol. 2016, 67, 2161–2176. [Google Scholar] [CrossRef] [PubMed]
- Silver, S.E.; Barrs, R.W.; Mei, Y. Transplantation of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Cardiac Regenerative Therapy. Front. Cardiovasc. Med. 2021, 8, 707890. [Google Scholar] [CrossRef] [PubMed]
- Shanak, S.; Helms, V. DNA methylation and the core pluripotency network. Dev. Biol. 2020, 464, 145–160. [Google Scholar] [CrossRef]
- Chin, M.H.; Mason, M.J.; Xie, W.; Volinia, S.; Singer, M.; Peterson, C.; Ambartsumyan, G.; Aimiuwu, O.; Richter, L.; Zhang, J.; et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009, 5, 111–123. [Google Scholar] [CrossRef]
- Newman, A.M.; Cooper, J.B. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 2010, 7, 258–262. [Google Scholar] [CrossRef]
- De Korte, T.; Katili, P.A.; Mohd Yusof, N.A.N.; van Meer, B.J.; Saleem, U.; Burton, F.L.; Smith, G.L.; Clements, P.; Mummery, C.L.; Eschenhagen, T.; et al. Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell-derived cardiomyocytes: Fit for purpose or forever elusive? Annu. Rev. Pharmacol. Toxicol. 2020, 6, 529–551. [Google Scholar] [CrossRef] [PubMed]
- Smith, A.S.T.; Macadangdang, J.; Leung, W.; Laflamme, M.A.; Kim, D.H. Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol. Adv. 2017, 35, 77–94. [Google Scholar] [CrossRef] [PubMed]
- Vo, Q.D.; Saito, Y.; Nakamura, K.; Iida, T.; Yuasa, S. Induced pluripotent stem cell-derived cardiomyocytes therapy for ischemic heart disease in animal model: A meta-analysis. Int. J. Mol. Sci. 2024, 25, 987. [Google Scholar] [CrossRef]
- Vučković, S.; Dinani, R.; Nollet, E.E.; Kuster, D.W.; Buikema, J.W.; Houtkooper, R.H.; Nabben, M.; van der Velden, J.; Goversen, B. Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: Lessons from maturation and disease modeling. Stem Cell Res. Ther. 2022, 13, 332. [Google Scholar] [CrossRef] [PubMed]
- Pourrier, M.; Fedida, D. The emergence of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a platform to model arrhythmogenic diseases. Int. J. Mol. Sci. 2020, 21, 657. [Google Scholar] [CrossRef] [PubMed]
- McDermott-Roe, C.; Lv, W.; Maximova, T.; Wada, S.; Bukowy, J.; Marquez, M.; Lai, S.; Shehu, A.; Benjamin, I.; Geurts, A.; et al. Investigation of a dilated cardiomyopathy–associated variant in BAG3 using genome-edited iPSC-derived cardiomyocytes. JCI Insight 2019, 4, e128799. [Google Scholar] [CrossRef] [PubMed]
- Ovics, P.; Regev, D.; Baskin, P.; Davidor, M.; Shemer, Y.; Neeman, S.; Ben-Haim, Y.; Binah, O. Drug development and the use of induced pluripotent stem cell-derived cardiomyocytes for disease modeling and drug toxicity screening. Int. J. Mol. Sci. 2020, 21, 7320. [Google Scholar] [CrossRef] [PubMed]
- Hnatiuk, A.P.; Briganti, F.; Staudt, D.W.; Mercola, M. Human iPSC modeling of heart disease for drug development. Cell Chem. Biol. 2021, 28, 271–282. [Google Scholar] [CrossRef] [PubMed]
- Wei, F.; Pence, L.; Woodling, K.; Bagam, P.; Beger, R.; Gamboa da Costa, G.; Pang, L. Effects of serum and compound preparation methods on delayed repolarization evaluation with human iPSC-CMs. Toxicol. Sci. 2022, 188, 48–61. [Google Scholar] [CrossRef]
- Cashman, J.R. Reengineering Mexiletine by chemical synthesis to decrease toxicity and improve pharmacological properties with patient-derived iPSC cardiomyocytes. Arch. Clin. Toxicol. 2022, 4, 5–10. [Google Scholar]
- Huang, C.Y.; Nicholson, M.W.; Wang, J.Y.; Ting, C.Y.; Tsai, M.H.; Cheng, Y.C.; Liu, C.L.; Chan, D.Z.H.; Lee, Y.C.; Hsu, C.C.; et al. Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons. Cell Rep. 2022, 39, 110643. [Google Scholar] [CrossRef]
- Denning, C.; Borgdorff, V.; Crutchley, J.; Firth, K.S.; George, V.; Kalra, S.; Kondrashov, A.; Hoang, M.D.; Mosqueira, D.; Patel, A.; et al. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim. Biophys. Acta 2016, 1863, 1728–1748. [Google Scholar] [CrossRef]
- Yang, X.L.; Pabon, L.; Murry, C.E. Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 2014, 114, 511–523. [Google Scholar] [CrossRef] [PubMed]
- Wu, P.; Deng, G.; Sai, X.; Guo, H.; Huang, H.; Zhu, P. Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes. Biosci. Rep. 2021, 41, BSR20200833. [Google Scholar] [CrossRef]
- Lundy, S.; Zhu, W.; Regnier, M.; Laflamme, M.A. Structural and functional maturation of cardiomyocytes derived from stem cells. Stem Cells Dev. 2013, 22, 1991–2002. [Google Scholar] [CrossRef] [PubMed]
- Körner, A.; Mosqueira, M.; Hecker, M.; Ullrich, N.D. Substrate stiffness influences structural and functional remodeling in induced pluripotent stem cell-derived cardiomyocytes. Front. Physiol. 2021, 12, 710619. [Google Scholar] [CrossRef] [PubMed]
- Crestani, T.; Steichen, C.; Neri, E.; Rodrigues, M.; Fonseca-Alaniz, M.H.; Ormrod, B.; Holt, M.R.; Pandey, P.; Harding, S.; Ehler, E.; et al. Electrical stimulation applied during differentiation drives the hiPSC-CMs towards a mature cardiac conduction-like cells. Biochem. Biophys. Res. Commun. 2020, 533, 376–382. [Google Scholar] [CrossRef] [PubMed]
- Lyra-Leite, D.M.; Gutiérrez-Gutiérrez, Ó.; Wang, M.; Zhou, Y.; Cyganek, L.; Burridge, P.W. A review of protocols for human iPSC culture, cardiac differentiation, subtype-specification, maturation, and direct reprogramming. STAR Protoc. 2022, 3, 101560. [Google Scholar] [CrossRef]
- Dou, W.; Wang, L.; Malhi, M.; Liu, H.; Zhao, Q.; Plakhotnik, J.; Xu, Z.; Huang, Z.; Simmons, C.A.; Maynes, J.T.; et al. A microdevice platform for characterizing the effect of mechanical strain magnitudes on the maturation of iPSC-Cardiomyocytes. Biosens. Bioelectron. 2021, 175, 112875. [Google Scholar] [CrossRef]
- Huang, C.Y.; Maia-Joca, R.P.; Ong, C.S.; Wilson, I.; DiSilvestre, D.; Tomaselli, G.F.; Reich, D.H. Enhancement of human iPSC-derived cardiomyocyte maturation by chemical conditioning in a 3D environment. J. Mol. Cell. Cardiol. 2020, 138, 1–11. [Google Scholar] [CrossRef]
- Ziang, Y.; Miller, K.; Guan, J.; Kiratitanaporn, W.; Tang, M.; Chen, S. 3d Bioprinting of complex tissues in vitro state-of-the-art and future perspectives. Arch. Toxicol. 2022, 96, 691–710. [Google Scholar]
- Fukuda, K. Establishment and Industrialization of a New Treatment Method Using Regenerative Cardiomyocyte Transplantation for Refractory Severe Heart Failure-Secondary Publication. JMA J. 2023, 6, 388–392. [Google Scholar] [PubMed]
- Kishino, Y.; Fukuda, K. Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments. Biomedicines 2023, 11, 915. [Google Scholar] [CrossRef] [PubMed]
- Tadevosyan, K.; Igesias-Garcia, O.; Mazo, M.M.; Prósper, F.; Raya, A. Engineering and assessing cardiac tissue complexity. Int. J. Mol. Sci. 2021, 22, 1479. [Google Scholar] [CrossRef] [PubMed]
- Fang, Y.H.; Wang, S.P.; Chang, H.Y.; Yang, P.J.; Liu, P.Y.; Liu, Y.W. Immunogenicity in stem cell therapy for cardiac regeneration. Acta Cardiol. Sin. 2020, 36, 588. [Google Scholar] [PubMed]
- Mattapally, S.; Pawlik, K.M.; Fast, V.G.; Zumaquero, E.; Lund, F.E.; Randall, T.D.; Townes, T.M.; Zhang, J. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell0derived cells: Universal donor for cell therapy. J. Am. Heart Assoc. 2018, 7, e010239. [Google Scholar] [CrossRef] [PubMed]
- Shiba, Y.; Gomibuchi, T.; Seto, T.; Wada, Y.; Ichimura, H.; Tanaka, Y.; Ogasawara, T.; Okada, K.; Shiba, N.; Sakamoto, K. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 2016, 538, 388–391. [Google Scholar] [CrossRef]
- Ogasawara, T.; Okano, S.; Ichimura, H.; Kadota, S.; Tanaka, Y.; Minami, I.; Uesugi, M.; Wada, Y.; Saito, N.; Okada, K. Impact of extracellular matrix on engraftment and maturation of pluripotent stem cell-derived cardiomyocytes in a rat myocardial infarct model. Sci. Rep. 2017, 7, 8630. [Google Scholar] [CrossRef]
- Stevens, K.R.; Murry, C.E. Human pluripotent stem cell-derived engineered tissues: Clinical considerations. Cell Stem Cell 2018, 22, 294–297. [Google Scholar] [CrossRef]
- Zheng, L.; Hu, Q.; Wang, X.; Mansoor, A.; Lee, J.; Feygin, J.; Zhang, G.; Suntharalingam, P.; Boozer, S.; Mhashilkar, A. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 2017, 115, 1866–1875. [Google Scholar] [CrossRef]
- Robey, T.E.; Saiget, M.K.; Reinecke, H.; Murry, C.E. Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell Cardiol. 2008, 45, 567–581. [Google Scholar] [CrossRef] [PubMed]
- Zhao, M.; Nakada, Y.; Wei, Y.; Bian, W.; Chu, Y.; Borovjagin, A.V.; Xie, M.; Zhu, W.; Nguyen, T.; Zhou, Y.; et al. Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived cardiomyocytes for myocardial repair in a swine model of myocardial infarction. Circulation 2021, 144, 210–228. [Google Scholar] [CrossRef] [PubMed]
- Lou, X.; Zhao, M.; Fan, C.; Fast, V.G.; Valarmathi, M.T.; Zhu, W.; Zhang, J. N-cadherin overexpression enhances the reparative potency of human induced pluripotent stem cell-derived cardiomyocytes in infarcted mouse hearts. Cardiovasc. Res. 2020, 116, 671–685. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Wu, J.; Qiang, B.; Romagnuolo, R.; Gagliardi, M.; Keller, G.; Laflamme, M.A.; Li, R.K.; Nunes, S.S. Transplanted microvessels improve pluripotent stem cell-derived cardiomyocyte engraftment and cardiac function after infarction in rats. Sci. Transl. Med. 2020, 12, eaax2992. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, T.; Sato, Y.; Yasuda, S.; Shikamura, M.; Tamura, T.; Takenaka, C.; Takasu, N.; Nomura, M.; Dohi, H.; Takahashi, M.; et al. Correlation between genetic abnormalities in induced pluripotent stem cell-derivatives and abnormal tissue formation in tumorigencity tests. Stem Cells Transl. Med. 2022, 11, 527–538. [Google Scholar] [CrossRef] [PubMed]
- Prieto Gonzalez, E.A. A multilevel approach to the causes of genetic instability in stem cells. In Handbook of Stem Cell Therapy; Springer: Singapore, 2022; pp. 1–55. [Google Scholar]
- Kim, J.Y.; Nam, Y.; Rim, Y.A.; Ju, J.H. Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells. Stem Cell Rev. Rep. 2022, 18, 142–154. [Google Scholar] [CrossRef] [PubMed]
- Okano, T.; Yamada, N.; Sakai, H.; Sakurai, Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J. Biomed. Mater. Res. 1993, 27, 1243–1251. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, M.; Miyagawa, S.; Miki, K.; Saito, A.; Fukushima, S.; Higuchi, T.; Kawamura, T.; Kuratani, T.; Daimon, T.; Shimizu, T.; et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012, 126, S29–S37. [Google Scholar] [CrossRef] [PubMed]
- Kawamura, M.; Miyagawa, S.; Fukushima, S.; Saito, A.; Miki, K.; Funakoshi, S.; Yoshida, Y.; Yamanaka, S.; Shimizu, T.; Okano, T.; et al. Enhanced therapeutic effects of human iPS cell derived cardiomyocyte by combined cell-sheets with omental flap technique in porcine ischemic cardiomyopathy model. Sci. Rep. 2017, 7, 8824. [Google Scholar] [CrossRef]
- Ishida, M.; Miyagawa, S.; Saito, A.; Fukushima, S.; Harada, A.; Ito, E.; Ohashi, F.; Watabe, T.; Hatazawa, J.; Matsuura, K.; et al. Transplantation of human-induced pluripotent stem cell derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. Transplantation 2019, 103, 291–298. [Google Scholar] [CrossRef]
- Kawamura, T.; Ito, Y.; Ito, E.; Takeda, M.; Mikami, T.; Taguchi, T.; Mochizuki-Oda, N.; Sasai, M.; Shimamoto, T.; Nitta, Y.; et al. Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: First three case reports. Front. Cardiovasc. Med. 2023, 10, 1182209. [Google Scholar] [CrossRef] [PubMed]
- Oikonomopoulos, A.; Kitani, T.; Wu, J.C. Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation. Mol. Ther. 2018, 26, 1624–1634. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.W.; Chen, B.; Yang, X.; Fugate, J.A.; Kalucki, F.A.; Futakuchi-Tsuchida, A.; Couture, L.; Vogel, K.W.; Astley, C.A.; Baldessari, A.; et al. Erratum: Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat. Biotechnol. 2018, 36, 899. [Google Scholar] [CrossRef] [PubMed]
- Ensminger, S.; Fujita, B.; Aboud, A.; Paitazoglou, C.; Eitel, I.; Jurczyk, D.; Mezger, M.; Yebran, F.; Kutschka, I.; Tiburcy, M.; et al. Safety and efficacy of induced pluripotent stem cell-derived engineered human myocardium as biological ventricular assist tissue in terminal heart failure (BioVAT-DZHK20): Trial design and experience at UKSH Lubeck. Thorac. Cardiovasc. Surg. 2024, 72, S1–S68. [Google Scholar]
- Mallapaty, S. Revealed: Two men in China were first to receive pioneering stem-cell treatment for heart disease. Nature 2020, 581, 249–250. [Google Scholar] [CrossRef]
- Zhang, H.; Xue, Y.; Pan, T.; Zhu, X.; Chong, H.; Xu, C.; Fan, F.; Cao, H.; Zhang, B.; Pan, J.; et al. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: Protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open 2022, 12, e056264. [Google Scholar] [CrossRef]
Clinical Trial | Sponsor | Study Title | Inclusion | Intervention | Sample Size | Start Date | Country |
---|---|---|---|---|---|---|---|
NCT 03763136 Single-Blind RCT Phase I/IIa | Help Therapeutics, Nanjing University Medical School | Epicardial injection of allogeneic human pluripotent stem cell- derived cardiomyocytes to treat severe chronic heart failure | Chronic LV dysfunction LVEF 20–45% 35–75 years old NYHA Class III-IV | Intramyocardial injection of allogeneic iPSC-CMs at time of CABG surgery | 20 | May 2019 | China |
NCT 04696328 None-Masking Single-Arm Trial | Cuorips Inc., Osaka University Hospital | Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for ischemic cardiomyopathy | Ischemic cardiomyopathy LVEF ≤ 35% ≥20 years old NYHA Class III-IV | Transplantation of human (allogeneic) iPSC-CM Sheet | 8 | December 2019 | Japan |
NCT 04396899 None-Masking Single-Arm Trial Phase I/II | Repairon, University Medical Center Goettingen | Safety and efficacy of induced pluripotent stem cell-derived engineered human myocardium as biological ventricular assist tissue in terminal heart failure | HFrEF LVEF < 35% 18–80 years old NYHA Class III-IV | Implantation of Engineered Human Myocardium (EHM) on dysfunctional left or right ventricular myocardium | 53 | February 2020 | Germany |
jRCTa 032200189 None-Masking Single-Arm Trial Phase I/II | Heartseed Inc., Keio University School of Medicine | Safety study of induced pluripotent stem cell-derived cardiac spheres transplantation (IPSCS study) | HFrEF LVEF 15–40% 20–75 years old NYHA Class III-IV | Intramyocardial injection of iPSC-CMs spheroids at time of CABG surgery | 10 | November 2020 | Japan |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sugiura, T.; Shahannaz, D.C.; Ferrell, B.E. Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. Int. J. Mol. Sci. 2024, 25, 5772. https://doi.org/10.3390/ijms25115772
Sugiura T, Shahannaz DC, Ferrell BE. Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. International Journal of Molecular Sciences. 2024; 25(11):5772. https://doi.org/10.3390/ijms25115772
Chicago/Turabian StyleSugiura, Tadahisa, Dhienda C. Shahannaz, and Brandon E. Ferrell. 2024. "Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells" International Journal of Molecular Sciences 25, no. 11: 5772. https://doi.org/10.3390/ijms25115772